The purpose of this research is to evaluate the extent of COVID-19 risk and perceived risk among Centre County residents and students, and how those risks evolve from the time isolation guidelines were implemented through a return to normal functioning.Participants in this research will complete an electronic survey with questions about their demographic, about their exposure to COVID-19, and about how COVID-19 has affected their health and work/education. Data from this research will be used to inform Centre County planning authorities and the Pennsylvania State University about the needs of communities, including needs for information dissemination and for potentially actionable, local interventions in response to the COVID-19 pandemic.

Participants complete an electronic survey.

To assess the efficacy and safety of early administration of vitamin D3 (cholecalciferol) in reducing mortality and morbidity for vitamin D deficient patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and mortality.

Restrictive (vs liberal) fluid treatment strategy during the first 24 hours of resuscitation for sepsis-induced hypotension will reduce 90-day in-hospital mortality.

We are experiencing global outbreak of coronavirus (COVID-19) recently. Millions of people are suffering and dying every day, in spite of putting our best efforts. We are doing this survey to understand people’s reaction to this situation. The survey will ask about your knowledge, practices and worries. Your response will help us to understand how to better control these situations. Your feedback is highly important to us, as we need to find out the best way to stop the disease from spreading and killing thousands of lives, and to reduce the stress among the population.

This phase 3b study will evaluate long-term safety and efficacy ofCSL312 (also known as garadacimab) when administeredsubcutaneously (SC) once monthly for at least 12 months.Subjects entering CSL312_3002 will be from 3 sources:• Subjects who participated in Study CSL312_2001• Subjects who participated in Study CSL312_3001• CSL312-naïve HAE subjects who have not participated ineither of the above studies

During the study, you will be expected to self-administer the study medication by injection under the skin once a month, complete a daily diary, provide blood and urine samples, complete questionnaires, undergo physical exams and have your vital signs recorded.You will visit the site 12 times.

$80.00 plus travel reimbursement

The main purpose of the study is to evaluate the safety and tolerability of an injection of the study drug in participants with Hereditary Angioedema. This study is open-label, which means that everyone in the study will receive the study drug and no participant will receive a placebo.

The study will last approximately for one year, with a total of approximately 11-16 study site visits. You will have your blood drawn at every study site visit, urine collected, pregnancy test if applicable, and receive study drug. You will also complete questionnaires and be contact weekly by the study site.

We wish to investigate the role of a specific gene in visceral pain sensation and perception. This gene, Nav1.8 has a known change present in 10% of the population which may affect the way we feel inflammatory pain in the gut. This is an important symptom in inflammatory bowel disease (IBD). Some patients feel high levels of pain we would like to control, other patients feel little to no pain in the presence of very active disease, which can lead to dangerously under-treated disease. In this study, we will use healthy volunteers as well as IBD patients, and test their sensitivity using rectal balloon dilation.Research subjects will be asked to fast, skipping solid foods and opaque liquids for 6 hours before the testing. Usually this means skipping 1 meal. At the beginning of the study visit. they will use an over the counter enema to clear their rectum of any stool. Healthy control subjects that have never had a colonoscopy before and all IBD patients will undergo a very brief proctoscopy to either verify rectal health or check for any IBD disease activity. Healthy controls that have had a prior colonoscopy within the last 5 years will skip that prior step. Then a trained physician on the research team will insert a thin, lubricated tube into the rectum, which will be inflated to specific pressures. Most of these tests will be designed to measure any change in sensation, then the need to use the toilet, followed by urgent need or discomfort, and lastly the lower threshold of pain. Test subjects will be able to stop testing at any time, should they become too uncomfortable. The testing takes between 1 and 1 and a half hours, and volunteers are compensated $200 for their time.

To simulate abdominal pain, we use a thin tube placed in the rectum that inflates a small balloon to very precise and safe pressures. Our bodies interpret these pressures (in ascending order) as the need to go to the bathroom; first just a little, then with increasing urgency and eventually discomfort and pain. During these experiments, we only measure the lower threshold of pain, and stop immediately when you tell us to stop. We have significant experience using this approach and we have found it consistently informative while causing the least amount of discomfort possible. The whole thing takes about an hour and we’re paying volunteers $200 for participating. We'll ask that you skip a meal before the study visit, and perform an over-the-counter enema at the start of the visit.

$200

This human study will test the impact of dietary supplement vegicaps containing Korean Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and other germs and natural killer (NK) cells that kill virus-infected cells and cancers. We had done an earlier study with Korean Angelica supplement and discovered even a single dose of it increased blood neutrophils and NK cells within 24 h. In the new study, Korean Angelica capsules (Cogni.Q) will be compared head-to-head with dummy (placebo) capsules. This is to make sure the immune boosting actions are really from the Korean Angelica supplement.Approximately 40 men will take part in this research study at Hershey Medical Center.

This study will investigate the changes in the human fecal microbiomes and resistomes in response to antibiotic treatment.

BMN 331 is an experimental drug that is being tested for the treatment of patients with HAE. This study is the first time BMN 331, which is a gene therapy, is being used in humans. BMN 331 is given only once during this research study and it is given as an infusion. The purpose of this study is to find out what effects, good and/or bad, the Study Drug has on you and your HAE.

You will have a total of 68 in person visits over 68 months where there will be blood drawn and other lab tests. You will have to travel to an off site location to receive the drug once and travel will be paid for by the sponsor of the trial.

The purpose of this research is to investigate the associations between depressive symptoms and inflammation. The researchers are studying how specific symptoms of depression (such as fatigue, sadness, impaired concentration, and loss of pleasure) are related to markers of inflammation, which is a key component of our immune system. Volunteers with depressive symptoms, as well as volunteers without depressive symptoms are needed for this research study. This study includes an online survey to determine eligibility and one in-lab visit. Participants who are eligible will be scheduled for one in-lab visit (2.5-3h for participants with depressive symptoms & 1-2h for participants without depressive symptoms), where they will be asked to answer surveys with questions related to depressive symptoms and complete a number of tasks (using an iPad and a touch screen phone) that measure thinking skills including attention, memory and reaction time. Participants will also undergo a single blood draw to assess inflammatory markers.

Participation will require one in person visit at the CRC that takes from 1 to 1.5 hours total where they will have their blood drawn, fill out surveys about their mood, and complete cognitive tests.

30

The purpose of the study is to test how social decisions are affected by possible risk of infection. We aim to examine how choices in a risky social decision-making situation can influenced by viewing images of infection threat (e.g., person with runny nose) vs. images of neutral scenes or other threatening scenes.

There will be one 90-minute in-person visit. Participants will be asked to have electrodes placed on their skin to record their physiological signals, answer questionnaires, and complete a decision-making task on the computer while looking at different images.

$30

Adults recently diagnosed with SARS-CoV-2 infection who use a 4-day combined intervention of nasal washes with 1% baby shampoo solution and oral gargles with Listerine Antiseptic® will have a reduced SARS-CoV-2 viral load compared to those using nasal and oral washes with normal saline. This combined intervention should be acceptable, tolerable and safe in this population. To test this, we are conducting a trial comparing the efficacy of a number of washes in reducing the oral and nasal SARS-CoV-2 viral load amongst adults.

At their home, participants will perform three nasal and oral rinses per day for 4 days and self-swab the nose and mouth before and after each morning rinse to collect specimens under the guidance of a zoom visit. On the morning of the 5th day participants will also self swab the nose and mouth for a final collection specimen. Participants will answer questions on an app and online platform.

100

We are evaluating patients who have been infected with Babesia. Babesia is a blood parasite that is acquired from ticks. The number of cases seen in Pennsylvania every year has been increasing. We intend to evaluate the blood of patients acutely infected with Babesiosis and review for possible simultaneous co-infections. We will compare those infected patients with the blood of healthy individuals. The goal is to identify proteins in the blood of acutely infected patients that are specific for Babesia and also evaluate the prevalence of patient's who have contracted a co-infection from the tick vector that transmitted the Babesia infection. The identification of the specific bacterial/parasitic antigens could then be used to create rapid diagnostic tests and help clinicians increase awareness of these tick-borne diseases.

We will obtain basic demographic information and past medical history. We will obtain two 10ml samples of blood. The blood will then be stored and ultimately sent to Antigen Discovery, Inc for proteomic array screening.

This study examines the experiences of international students with regard to upper respiratory illnesses, healthcare, and use of antibiotics in their home countries and in the United States. The findings of the study will inform the development of training to improve healthcare providers’ communication skills for discussing antibiotics with international students.

Complete one online survey, which takes approximately 20 minutes.

10.00

This trial will address the safety of withdrawing hydroxychloroquine (HCQ) in patients with systemic lupus erythematous who are 60 years of age or older. In this older population the benefits of HCQ are expected to decrease since disease activity decreases with advancing age. The study will test whether HCQ can be safely discontinued in stable/quiescent patients.

Participants will be in this study for about 1 year, during which time they will come to 7 visits in the research clinic. The first visit will take up to 2 hours and will include blood and urine sampling and completion of self-assessment questionnaires. Subsequent visits will take up to 1 hour. Participants will be randomized to receive either the active drug hydroxychloroquine or placebo. The treatment will be blinded to both the participant and the investigator. Diaries will be requested in which the participant keeps track of dosing of the study medication.

The purpose of this study is to investigate the underlying biological causes of the loss of pleasure in individuals diagnosed with depression. This study will examine brain, behavioral, and inflammatory markers of depression. Participants will answer questions, give blood and saliva, undergo fMRI and perform computer tasks. The study is also recruiting healthy controls with no history of major mental illnesses.Participants will be compensated $130 in total. To limit time in-person, the first portion of the study will be conducted remotely (1.5hrs), followed by an in-person appointment (3hrs). Mandatory COVID-19 precautions will be taken to ensure safety for the in-person appointment.

There will be one virtual visit where participants will review consent, answer questions about their mental health, and complete online questionnaires. There will also be one in-person visit where blood will be drawn, vitals (blood pressure, height, weight, and pulse) will be taken, participants will undergo an fMRI scan and complete computer tasks, and saliva samples will be collected at 3 time points.

$130

Wheezing is a common symptom of respiratory distress in infants and children. Infants who wheeze are at increased risk of being diagnosed with asthma, the most common chronic disease of childhood. This study aims to yield an objective measure of asthma risk using molecular markers obtained from saliva. Saliva miRNA (markers used in this study) levels will be measured using HiSeq technology. Refinement and validation of this measure in future large-scale studies could allow clinicians to accurately predict for families an infant’s risk of asthma and optimize medical management to prevent future hospitalizations.

If your child has a respiratory illness you will be asked to provide a saliva sample at one clinic visit. Six months after the initial encounter, you will be asked to do complete surveys designed to be done remotely at home.

$20.00

Voluntary research study is to test INBRX-101 as an experimental drug to treat patients with alpha-1 antitrypsin deficiency. The goal of this study is to evaluate the safety and study the therapeutic effects of INBRX-101 in AATD emphysema patients when compared with current approved AATD therapy with A1PI.

You will visit the study site up to a total of 37 times for blood sampling, computed tomography (CT) scan, lung function tests, electrocardiograms (ECGs), study drug administration and questionnaire completion.

Unknown at this time

The reproducibility, reliability, and validity of saliva collection techniques is an important issue that needs to be addressed to achieve consistency in the emerging field of mitochondrial psychobiology. The objective of the current study is to increase scientific rigor by utilizing robust and well-controlled methods in the collection and testing of saliva samples. Given the non-invasive and convenient nature of saliva collection, it is likely that research using saliva-derived cell-free mitochondrial DNA (cf-mtDNA) will increase. Therefore, to ensure that the results obtained from the current study are trustworthy and meaningful, we are proposing a small, highly controlled randomized study design that will integrate three methods of saliva collection. The study will adopt a rigorous and systematic approach to data collection, analysis, and interpretation. Through the implementation of these methods, we seek to achieve a higher degree of accuracy and reliability in cf-mtDNA saliva-based measurements.

Each participant will be asked to collect 3 randomized saliva samples (i.e., one static Salivette®, one active Salivette®, and either a second active Salivette® or a passive drool) upon awakening for 10 business days. All collection materials be pre-labeled with the day, type of sample, and order to make it easy for participants to quickly and accurately deposit samples upon awakening. Once saliva samples are collected, participants will be asked to promptly return the samples to the provided plastic bag and store the bag in their at-home freezers. All samples will be stored there until the end of the 10-day study. After the saliva is returned to the freezer, participants will complete a short (3-5 min) morning survey on the provided mobile device which has been pre-loaded with the M2C2 application. The morning survey asks questions about sleep, morning outlook, and anticipatory stress and positive experiences. In the evenings, participants will be prompted (via banner notification on screen and audible beep) to complete a slightly longer (8-10 min) survey. This survey asks questions about the respondent’s daily experiences (stressors, mood, physical symptoms). Within the application, there are three brief, objective cognitive tasks. Upon completion of the 10-day protocol, respondents will return the mobile device and saliva samples. Participants may bring all saliva samples back to the lab during regular business hours, or they may schedule a time for a member of the study team to pick up the samples. Depending on the distance between the laboratory and the participant’s home, the need for ice packs will be assessed on an individual basis.

50

The purpose of this study is to gain a greater understanding of healthcare workers’ knowledge of and perception of dysphagia in older adults. Study participants will fill out a survey/questionnaire in a single study session. This is expected to take 15-20 minutes.

You will be asked to complete a single, brief survey. It will take no more than 15-20 minutes.